CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder

References

• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 ;69:1789–1799.
   Web of Science ®Google Scholar
• Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539–1545.
   PubMed Web of Science ®Google Scholar
• Sacktor N, McDermott MP, Marder K, et al. HIVassociated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136–142.
   PubMed Web of Science ®Google Scholar
• Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2007;16:94–98.
   Google Scholar
• Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorder before and during the era of combination antiretroviral therapy: differences in rates, nature and predictors. J Neurovirol. 2011;17:3–16.
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009;23:83–87.
   PubMed Web of Science ®Google Scholar
• Menten P Struyf S, Schutyser E, et al. The LD78beta isoform of MIP- 1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest. 1999;104:R1–R5.
   PubMed Web of Science ®Google Scholar
• Roberts TK, Buckner CM, Berman JW. Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS. Front Biosci. 2010;15:478–536.
   PubMed Web of Science ®Google Scholar
• Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis. 2010;37:542–548.
   Web of Science ®Google Scholar
• Xin X, Shioda T, Kato A, Liu H, Sakai Y, Nagai Y Enhanced anti- HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha. FEBS Lett. 1999;457:219–222.
   PubMed Web of Science ®Google Scholar
• Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem. 1999;274:17478–17483.
   PubMed Web of Science ®Google Scholar
• Aquaro S, Menten P, Struyf S, et al. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5 dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol. 1999;75:4402–4406.
   Web of Science ®Google Scholar
• Colobran R, Pedrosa E, Carretero-Iglesia L, Juan M. Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease. Clin Exp Immunol. 2010;162:41–52.
   Web of Science ®Google Scholar
• Townson JR, Barcellos LF, Nibbs RJB. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol. 2002;32:3016–3026.
   PubMed Web of Science ®Google Scholar
• Nakao M, Nomiyama H, Shimada K. Structures of human genes coding for cytokine LD78 and their expression. Mol Cell Biol. 1990;10:3646–3658.
   PubMed Web of Science ®Google Scholar
• Irving S, Zipfel P, Balke J, et al. Two inflammatory mediator cytokine genes are closely linked and variably amplified on chromosome 17q. Nucleic Acids Res. 1990;18:3261–3270.
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplication on HIV-1/AIDS susceptibility. Science. 2005;307:1434–1440.
   PubMed Web of Science ®Google Scholar
• Colobran R, Comas D, Faner R, et al. Population structure in copy number variation and SNPs in the CCL4L chemokine gene. Genes Immun. 2008:279–288.
   Web of Science ®Google Scholar
• Chun H, Hao W, Honghai Z, Ning L, Yasong W, Chen D. CCL3L1 prevents gp120-induced neuron death via the CREB cell signaling pathway. Brain Res. 2009;1257:75–88.
   Web of Science ®Google Scholar
• Sacktor N. The epidemiology of human immunodeficiency virus- associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8:115–121.
   PubMed Web of Science ®Google Scholar
• Marder K, Albert SM, McDermott MP, et al. Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology. 2003;60:1467–1473.
   PubMed Web of Science ®Google Scholar
• Morgello S, Gelman BB, Kozlowski PB, et al. The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol. 2001;27:326–335.
   PubMed Web of Science ®Google Scholar
• Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158:1079–1083.
   PubMed Web of Science ®Google Scholar
• Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136–142.
   PubMed Web of Science ®Google Scholar
• Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol. 2009;15:360–370.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Nyaku M, Edberg J. Variations in CCL3L gene cluster sequence and non-specific gene copy numbers. BMC Res Notes. 2010;3:74.
   Google Scholar
• Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus- associated dementia. Ann Neurol. 1998;44:831–835.
   PubMed Web of Science ®Google Scholar
• Spector SA, Singh KK, Gupta S, et al. APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV- infected plasma donors. AIDS. 2010;24:1471–1479.
   PubMed Web of Science ®Google Scholar
• Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV- associated dementia. Neurology. 1998;50:1814–1820.
   PubMed Web of Science ®Google Scholar
• Valcour V Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C. Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol. 2008;14:362–367.
   PubMed Web of Science ®Google Scholar
• Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur JC. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry. 2008;20:25–31.
   PubMed Web of Science ®Google Scholar
• Ances BM, Vaida F, Yeh MJ, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis. 2010;201:336–340.
   Web of Science ®Google Scholar
• Kulkarni H, Marconi VC, Agan BK, et al. Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy. PLoS One. 2008;3:e3671.
   Web of Science ®Google Scholar
• Kulkarni H, Agan BK, Marconi VC, et al. CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals. PLoS One. 2008;3:e3165.
   Web of Science ®Google Scholar
• Dolan M, Kulkarni H, Camargo J, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol. 2007;8:1324–1336.
   PubMed Web of Science ®Google Scholar
• Ahuja SK, Kulkarni H, Catano G, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008;14:413–420.
   PubMed Web of Science ®Google Scholar
• Shostakovich-Koretskaya L, Catano G, Chykarenko ZA, et al. Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS. 2009;23:679–688.
   Web of Science ®Google Scholar
• Shalekoff S, Meddows-Taylor S, Schramm DB, et al. Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women. J Acquir Immune Defic Syndr. 2008;48:245–254.
   Web of Science ®Google Scholar
• Meddows-Taylor S, Donninger SL, Paximadis M, et al. Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission. J Gen Virol. 2006;87:2055–2065.
   Web of Science ®Google Scholar
• Kuhn L, Schramm DB, Donninger SL, et al. African infants’ CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS. 2007;21:1753–1761.
   Web of Science ®Google Scholar
• Urban TJ, Weintrob AC, Fellay J, et al. CCL3L1 and HIV/AIDS susceptibility. Nat Med. 2009;15:1110–1112.
   PubMedGoogle Scholar
• Bhattacharya T, Stanton J, Kim EY, et al. CCL3L1 and HIV/AIDS susceptibility. Nat Med. 2009;15:1112–1115.
   PubMedGoogle Scholar
• Salgado M, Simón A, Sanz-Minguela B, et al. An additive effect of protective host genetic factors correlates with HIV nonprogression status. J Acquir Immune Defic Syndr. 2011;56:300–305.
   Web of Science ®Google Scholar